May 14 (Reuters) - Daiichi Sankyo Co Ltd:
* ZYMEWORKS AND DAIICHI SANKYO EXPAND IMMUNO-ONCOLOGY COLLABORATION FOCUSED ON BISPECIFIC ANTIBODIES
* ZYMEWORKS- TO GET UPFRONT TECHNOLOGY ACCESS FEE OF $18 MILLION; MAY GET UP TO $466.7 MILLION IN POTENTIAL CLINICAL, REGULATORY, COMMERCIAL MILESTONE PAYMENTS
* ZYMEWORKS INC - ZYMEWORKS WILL RECEIVE UP TO DOUBLE-DIGIT TIERED ROYALTIES ON GLOBAL PRODUCT SALES
* ZYMEWORKS - DAIICHI SANKYO TO ACQUIRE LICENSES TO CO’S AZYMETRIC AND EFECT TECHNOLOGY PLATFORMS TO DEVELOP 2 ADDITIONAL BISPECIFIC ANTIBODY THERAPEUTICS Source text for Eikon: Further company coverage:
